{"prompt": "['2016N298481_02', 'CONFIDENTIAL', '205270', 'For any cardiovascular events detailed in Section 9.3.5 and Section 9.3.6 and all deaths,', 'whether or not they are considered SAEs, specific Cardiovascular (CV) and Death', 'sections of the CRF will be required to be completed. These sections include questions', 'regarding cardiovascular (including sudden cardiac death) and non-cardiovascular death.', 'The CV eCRFs are presented as queries in response to reporting of certain CV MedDRA', 'terms. The CV information should be recorded in the specific cardiovascular section of', 'the CRF within one week of receipt of a CV Event data query prompting its completion.', '9.3.7.', 'Adverse Events of Special Interest', 'The investigator or site staff will be responsible for detecting, documenting and reporting', 'any events that may represent the AEs of special interest listed below (using preferred', 'terms):', 'Death, MI, stroke, heart failure, thromboembolic events, thrombosis of vascular', 'access', 'Thrombosis and/or tissue ischemia secondary to excessive erythropoiesis', 'Worsening of hypertension', 'Cardiomyopathy', 'Pulmonary artery hypertension (see also Section 9.3.2)', 'Cancer-related mortality or tumor progression and recurrence', 'Esophageal and gastric erosions', 'Proliferative retinopathy, macular edema, choroidal neovascularization', 'Exacerbation of rheumatoid arthritis', 'The Death CRF is provided immediately after the occurrence or outcome of death is', 'reported. Initial and follow-up reports regarding death must be completed within one', 'week of when the death is reported.', 'The results of any investigation regarding adverse events of special interest should be', \"recorded in the relevant sections of the participant's eCRF.\", '9.3.8.', 'Possible Suicidality Related Adverse Events', \"If during the study there is an occurrence of an AE or SAE which in the investigator's\", 'opinion, is possibly related to suicidality, the Possible Suicidality Related Adverse Events', '(PSRAE) eCRF form should be completed (in addition to the AE or SAE pages, as', 'appropriate).', 'This event may include, but is not limited to, one that involves suicidal ideation, a', 'preparatory act toward imminent suicidal behavior, a suicide attempt, or a completed', 'suicide. The investigator will exercise his or her medical and scientific judgment in', 'deciding whether an event is possibly related to suicidality.', '58']['2016N298481_02', 'CONFIDENTIAL', '205270', '9.3.9.', 'Pregnancy', 'Details of all pregnancies in female participants will be collected after the start of', 'study treatment and until seven days after the last dose.', 'If a pregnancy is reported, the investigator should inform Sponsor within 2 weeks of', 'learning of the pregnancy and should follow the procedures outlined in Section 12.5', '(Appendix 5) .', 'Abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth,', 'congenital anomalies, ectopic pregnancy) are considered SAEs.', '9.4.', 'Treatment of Overdose', 'There is no specific antidote for overdose with daprodustat. The expected manifestations', 'of daprodustat overdosage include signs and symptoms associated with an excessive', 'and/or rapid increase in Hgb concentration. Daprodustat is highly protein bound; thus,', 'clearance of daprodustat by hemodialysis (HD) or peritoneal dialysis (PD) is very low', 'and these are not effective methods to enhance the elimination of daprodustat.', 'Daprodustat metabolites are, in part, cleared via hemodialysis. In the event of a suspected', 'overdose, it is recommended that the appropriate supportive clinical care be instituted, as', \"dictated by the participant's clinical status. Additionally, participants should be\", 'monitored closely for CV events, increased heart rate and hematologic abnormalities.', '9.5.', 'Safety Assessments', 'Planned time points for all safety assessments are provided in the SoA (Section 2).', '9.5.1.', 'Height and Weight', 'Height and weight will be measured as specified in the SoA (Section 2). Weight', 'should be measured with the participant wearing indoor daytime clothing with no', 'shoes.', '9.5.2.', 'Blood Pressure and Heart Rate', 'Measurement of systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart', 'rate (HR) will be taken at the time points specified in the SoA (Section 2)', 'One measurement each of SBP, DBP and HR will be taken except at Day 1 and', 'Week 28 (or Early Treatment Discontinuation visit) when SBP, DBP and HR', 'will be measured in triplicate.', 'For measurements taken in triplicate, the readings can be averaged and the', 'averaged value would be included in the eCRF.', 'Measurements will be taken with participants in a seated position after at least a', '5-minute rest period, and will be before collection of blood samples for', 'laboratory testing, where applicable.', '59']\n\n###\n\n", "completion": "END"}